Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.18 USD | +0.66% | +17.09% | +184.21% |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
May. 15 | Sector Update: Health Care Stocks Rise Pre-Bell Wednesday | MT |
Financials (USD)
Sales 2024 * | 160M | Sales 2025 * | 237M | Capitalization | 1.07B |
---|---|---|---|---|---|
Net income 2024 * | -189M | Net income 2025 * | -142M | EV / Sales 2024 * | 5.21 x |
Net cash position 2024 * | 231M | Net cash position 2025 * | 228M | EV / Sales 2025 * | 3.53 x |
P/E ratio 2024 * |
-5.44
x | P/E ratio 2025 * |
-7.85
x | Employees | 296 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.89% |
Latest transcript on Arcutis Biotherapeutics, Inc.
1 day | +0.66% | ||
1 week | +17.09% | ||
Current month | +10.34% | ||
1 month | -10.44% | ||
3 months | -1.29% | ||
6 months | +350.00% | ||
Current year | +184.21% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Watanabe
CEO | Chief Executive Officer | 55 | 15-12-31 |
Rajvir Madan
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
Jay Ramsinghani
COO | Chief Operating Officer | - | 20-05-26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Heron
CHM | Chairman | 53 | 16-03-31 |
Founder | 69 | 16-05-31 | |
Keith Leonard
BRD | Director/Board Member | 62 | 21-09-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 9.2 | +0.88% | 3,450,543 |
24-05-16 | 9.12 | -1.30% | 4,310,073 |
24-05-15 | 9.24 | +13.65% | 13,896,318 |
24-05-14 | 8.13 | +1.75% | 4,658,048 |
24-05-13 | 7.99 | +1.91% | 2,339,107 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+184.21% | 1.07B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ARQT Stock